X0708 D LIVE 0002152390 Bregma Capital Life Sciences Fund, LP 224 PRESIDIO AVE SAN FRANCISCO CA CALIFORNIA 94115 917-415-7223 DELAWARE Bregma Capital Life Science Fund, LP Limited Partnership true 2026 Mark E. Karvosky 224 Presidio Ave San Francisco CA CALIFORNIA 94115 Executive Officer CEO & CIO of Issuer's Investment Manager - Bregma Capital GP, LLC 224 Presidio Ave San Francisco CA CALIFORNIA 94115 Executive Officer Issuer's General Partner - Bregma Capital, LP 224 Presidio Ave San Francisco CA CALIFORNIA 94115 Executive Officer Issuer's Investment Manager Pooled Investment Fund Hedge Fund false Decline to Disclose 06b 3C 3C.7 false true true true false 1000000 Profor Securities, LLC 136084 None None 800 Westchester Ave Suite 641N Rye Brook NY NEW YORK 10573 AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA HI HAWAII IL ILLINOIS IN INDIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MO MISSOURI NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO OR OREGON PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA TN TENNESSEE TX TEXAS VA VIRGINIA WA WASHINGTON WV WEST VIRGINIA WI WISCONSIN false Indefinite 0 Indefinite false 0 0 0 The recipient disclosed in Item 12 will receive certain placement fees with respect to clients introduced to the Issuer, as disclosed to the applicable clients. 0 The Issuer's manager will receive a customary management fee and incentive payment, as described in the Issuer's offering documents. false Bregma Capital Life Sciences Fund, LP /s/ Mark E. Karvosky Mark E. Karvosky CEO & CIO of Issuer's Investment Manager 2026-08-31